Who Paid My Doc
Luis Cardenas
Surgical Critical Care Newark, DE Doctor of Osteopathy
NPI 1093033482 CMS profile 1077540
4735 Ogletown Stanton Road, Suite 3301, Newark, DE 19713
General payments
$740
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$6,500
Through program year 2025, Luis Cardenas of Newark, DE is reported in the CMS Open Payments database as having received $740 across 20 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,500 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 41st percentile of Surgical Critical Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $75 | 2 | |
| 2024 | General | $149 | 5 | |
| 2023 | General | $101 | 1 | |
| 2021 | General | $82 | 3 | |
| 2020 | General | $96 | 3 | |
| 2019 | General | $237 | 6 |
Beside peers
- Luis Cardenas
- Surgical Critical Care median
- Middle half of Surgical Critical Care
- National median
In program year 2025, general payments to Luis Cardenas were reported at $75. Among 1,068 Surgical Critical Care profiles paid that year, the median was $231 and the middle half received between $82 and $1,489.
Show as a table
| Year | Luis Cardenas | Surgical Critical Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $237 | $161 | $57–$631 | $163 |
| 2020 | $96 | $116 | $33–$383 | $114 |
| 2021 | $82 | $121 | $37–$475 | $132 |
| 2022 | $0 | $163 | $53–$789 | $149 |
| 2023 | $101 | $188 | $67–$1,031 | $160 |
| 2024 | $149 | $216 | $80–$1,133 | $164 |
| 2025 | $75 | $231 | $82–$1,489 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
485
Drug cost
$18,997
Branded share of claims
72.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Sodium Chloride 0.9 % Sodium Chloride | Brand | 150 | $7,704 | |
| Lactated Ringers Ringer's Solution,lactated | Brand | 119 | $3,802 | |
| Sodium Chloride Sodium Chloride 0.45 % | Brand | 53 | $2,262 | |
| Potassium Phosphate Potassium Phos,m-Basic-D-Basic | Brand | 14 | $1,940 | |
| Potassium Chloride | Generic | 52 | $1,871 | |
| Octreotide Acetate | Generic | 13 | $600 | |
| Magnesium Sulfate | Generic | 45 | $491 | |
| Famotidine | Generic | 23 | $256 | |
| Ondansetron Hcl Ondansetron Hcl/Pf | Brand | 16 | $71 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 42 billing codesPaid by Medicare
$56,094
Medicare patients
273
Services billed
404
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Ischemic heart disease | 44% | |
| Depression | 42% | |
| Diabetes | 40% | |
| Atrial fibrillation | 38% | |
| Chronic kidney disease | 35% | |
| Heart failure | 32% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
20 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Critical Care in Delaware
Related records
Surgical Critical Care in Delaware
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Critical Care
Everyone recorded under this specialty, nationwide.
Doctors in Delaware
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.